Trial Profile
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Dexamethasone; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eisai Inc
- 11 Jul 2022 Status changed from active, no longer recruiting to completed.
- 25 Jan 2015 Planned End Date changed from 1 Sep 2014 to 1 May 2015 as reported by ClinicalTrials.gov
- 14 Nov 2013 Planned end date changed from 1 Dec 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.